MedTrace Logo

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

NCT01304303 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2019-05-03

No results posted yet for this study

Summary

Phase I study of SPARC1023 alone and in combination with carboplatin

Conditions

  • Solid Tumor in Advanced Stage

Interventions

DRUG

SPARC1023 I

IV administration

DRUG

SPARC1023 II

IV administration

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304303 on ClinicalTrials.gov